Improving HIV testing and PrEP for transgender women through mHealth

通过移动医疗改善跨性别女性的艾滋病毒检测和 PrEP

基本信息

  • 批准号:
    10258220
  • 负责人:
  • 金额:
    $ 25.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-28 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

Abstract Despite decades of evidence-based interventions, including the 90/90/90 strategy, the HIV epidemic in Malaysia remains volatile. With over 100,000 cumulative HIV cases, Malaysia's rapidly expanding HIV epidemic is the fifth largest in the Asia-Pacific region and is concentrated within the most-at-risk populations. Originally driven by people who inject drugs, the majority of new infections today (>90%) are attributed to sexual transmission, many of which occur among transgender women (TGW). TGW are disproportionately impacted by HIV worldwide, with an estimated global prevalence of 19%. In Malaysia, an estimated 12.4% of TGW are living with HIV. TGW experience multi-level vulnerabilities to HIV, including discrimination in employment and economic opportunities, steering many TGW into high-risk occupations, such as sex work. High levels of stigma and discrimination against TGW by healthcare providers can foster a hostile environment toward TGW, complicating efforts to scale-up of HIV testing and prevention services among trans women, including pre-exposure prophylaxis (PrEP). Modeling studies suggest increased HIV testing and uptake of PrEP is the most impactful and cost-effective strategy for reducing new infections. Despite this, only 37% of TGW in Malaysia have ever been HIV tested. Similarly, while PrEP is recommended in Malaysia's National Strategic Plan to End AIDS (2016-2030), only 1 in 5 TGW has ever heard of PrEP. However, after learning about PrEP, more than 80% of TGW in Malaysia say they would take it. To scale-up of HIV testing and PrEP among TGW, innovative strategies are needed to rapidly overcome the complex barriers preventing uptake. In settings where anti-trans stigma is pervasive, such as Malaysia, mHealth may provide an empowering alternative approach to service delivery for TGW. An effective platform for reaching vulnerable and hidden populations, mHealth can overcome barriers associated with traditional clinic-based care by designing customized models of care tailored to the needs of vulnerable populations. Through confidential screening, rapid referrals to trans-friendly providers, and tools that facilitate access to gender-affirming health care needs, mHealth is a promising platform that can be leveraged for intervening around HIV prevention. Thus, we propose to develop and test a new clinic-affiliated app, called MyLink2care, to deliver an integrated HIV prevention intervention for TGW in Malaysia. Specifically, we propose to: 1) adapt, expand, and refine an existing mobile application by conducting formative research with TGW and clinical stakeholders to develop a prototype of the MyLink2Care app to undergo usability testing, followed by development of the beta version of the app; 2) conduct “beta testing” of the MyLink2Care app to assess its usability and acceptability; and 3) assess preliminary feasibility and acceptability of the MyLink2care app within a pilot, randomized-controlled trial, compared with treatment-as-usual for engagement in HIV prevention.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Roman Shrestha其他文献

Roman Shrestha的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Roman Shrestha', 18)}}的其他基金

Integrated online-to-offline (O2O) model of care for HIV prevention and treatment among men who have sex with men
男男性行为者艾滋病预防和治疗的线上线下(O2O)一体化护理模式
  • 批准号:
    10548402
  • 财政年份:
    2022
  • 资助金额:
    $ 25.43万
  • 项目类别:
Integrated online-to-offline (O2O) model of care for HIV prevention and treatment among men who have sex with men
男男性行为者艾滋病预防和治疗的线上线下(O2O)一体化护理模式
  • 批准号:
    10665762
  • 财政年份:
    2022
  • 资助金额:
    $ 25.43万
  • 项目类别:
An online HIV self-testing intervention with online-to-offline linkage to care for transgender women
在线艾滋病自检干预,线上线下联动,关爱跨性别女性
  • 批准号:
    10772677
  • 财政年份:
    2022
  • 资助金额:
    $ 25.43万
  • 项目类别:
Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSM
开发和测试移动应用程序以加强马来西亚男男性接触者的艾滋病毒预防级联
  • 批准号:
    10367278
  • 财政年份:
    2021
  • 资助金额:
    $ 25.43万
  • 项目类别:
Improving HIV testing and PrEP for transgender women through mHealth
通过移动医疗改善跨性别女性的艾滋病毒检测和 PrEP
  • 批准号:
    10398983
  • 财政年份:
    2021
  • 资助金额:
    $ 25.43万
  • 项目类别:
Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSM
开发和测试移动应用程序以加强马来西亚男男性接触者的艾滋病毒预防级联
  • 批准号:
    10261542
  • 财政年份:
    2021
  • 资助金额:
    $ 25.43万
  • 项目类别:
Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSM
开发和测试移动应用程序以加强马来西亚男男性接触者的艾滋病毒预防级联
  • 批准号:
    10673162
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Integrated rapid access to HIV prevention program for people who inject drugs (iRaPID)
注射吸毒者综合快速获得艾滋病毒预防计划 (iRaPID)
  • 批准号:
    10082915
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Training in MHealth Prevention with MSM
MSM 的 MHealth 预防培训
  • 批准号:
    10673645
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs (RAPID)
注射吸毒者综合快速艾滋病毒预防计划 (RAPID)
  • 批准号:
    10224917
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 25.43万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 25.43万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 25.43万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 25.43万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 25.43万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 25.43万
  • 项目类别:
Studies on cofactors for development of acquired immunodeficiency syndrome in feline immunodeficiency virus infection.
猫免疫缺陷病毒感染后获得性免疫缺陷综合征发生的辅助因子研究。
  • 批准号:
    03660315
  • 财政年份:
    1991
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 25.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了